Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

Arthritis Research and Therapy

Volumn 14, Issue SUPPL. 5, 2012, Pages

  Mei, Henrik E ^a,b   Schmidt, Stefanie ^a,b   Dörner, Thomas ^a,b  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIRHEUMATIC AGENT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; BLINATUMOMAB; CD19 ANTIBODY; EPRATUZUMAB; MD 1342; MEDI 551; MOR 208; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB; CD19 ANTIGEN; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ANTIGEN EXPRESSION; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; AUTOREACTIVE PLASMA CELL; B LYMPHOCYTE; CELL LINEAGE; CYTOPENIA; HUMAN; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMA CELL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; AUTOIMMUNE DISEASE; IMMUNOLOGY; METHODOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY; PLASMA CELLS;

MLCS; MLOWN;

EID: 84868675342     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3909     Document Type: Review

References (152)

1. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6:394-403. 10.1038/nri1838, 16622478.
2. Dorner T. SLE in 2011: deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol 2012, 8:68-70.
3. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178. 10.1038/nrrheum.2011.1, 21283146.
4. Reininger L, Radaszkiewicz T, Kosco M, Melchers F, Rolink AG. Development of autoimmune disease in SCID mice populated with long-term 'in vitro' proliferating (NZB × NZW)F1 pre-B cells. J Exp Med 1992, 176:1343-1353. 10.1084/jem.176.5.1343, 2119422, 1402680.
5. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, Mei H, Radtke H, Gromnica-Ihle E, Burmester GR, Arnold R, Radbruch A, Hiepe F. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009, 113:214-223. 10.1182/blood-2008-07-168286, 18824594.
6. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009, 5:433-441. 10.1038/nrrheum.2009.141, 19581902.
7. Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, Hoyer BF. Memory B and memory plasma cells. Immunol Rev 2010, 237:117-139. 10.1111/j.1600-065X.2010.00938.x, 20727033.
8. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, Manz RA. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003, 171:1684-1690.
9. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol 2011, 32:595-602. 10.1016/j.it.2011.09.001, 22001488.
10. Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 2011, 23:305-310. 10.1097/BOR.0b013e328344c15e, 3154025, 21330926.
11. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, Noelle RJ. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFFand APRIL. J Immunol 2008, 180:3655-3659.
12. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150. 10.1002/art.23047, 18050206.
13. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803. 10.1002/art.30373, 21452293.
14. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731. 10.1016/S0140-6736(10)61354-2, 21296403.
15. Geffroy-Luseau A, Jego G, Bataille R, Campion L, Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol 2008, 20:775-782. 10.1093/intimm/dxn035, 18397910.
16. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210. 10.1002/art.27189, 2857977, 20039404.
17. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56:3909-3918. 10.1002/art.22967, 18050222.
18. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11:R123. 10.1186/ar2789, 2745807, 19686595.
19. Mei HE, Frolich D, Giesecke C, Loddenkemper C, Reiter K, Schmidt S, Feist E, Daridon C, Tony HP, Radbruch A, Dorner T. Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab. Blood 2010, 116:5181-5190. 10.1182/blood-2010-01-266536, 20829370.
20. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146-2154. 10.1002/art.11181, 12905467.
21. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmstrom V, Trollmo C. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74. 10.1016/j.clim.2006.08.016, 17046329.
22. Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012, 71:1289-1296. 10.1136/annrheumdis-2011-200706, 3396459, 22307942.
23. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy?. Nat Rev Rheumatol 2011, 7:551-556. 10.1038/nrrheum.2011.108, 21808289.
24. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003, 3:822-829. 10.1038/nri1203, 14523388.
25. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dorner T. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009, 113:2461-2469. 10.1182/blood-2008-04-153544, 18987362.
26. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005, 5:230-242. 10.1038/nri1572, 15738953.
27. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev 2010, 237:140-159. 10.1111/j.1600-065X.2010.00940.x, 20727034.
28. Benner R, Hijmans W, Haaijman JJ. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol 1981, 46:1-8. 1536329, 7039877.
29. McMillan R, Longmire RL, Yelenosky R, Lang JE, Heath V, Craddock CG. Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production. J Immunol 1972, 109:1386-1394.
30. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997, 388:133-134. 10.1038/40540, 9217150.
31. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to longlived plasma cells. Immunity 1998, 8:363-372. 10.1016/S1074-7613(00)80541-5, 9529153.
32. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915. 10.1056/NEJMoa066092, 17989383.
33. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005, 23:367-386. 10.1146/annurev.immunol.23.021704.115723, 15771575.
34. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-1584. 10.1084/jem.20040168, 2211779, 15173206.
35. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67:1011-1016.
36. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750. 10.1038/nri1886, 16977339.
37. Miller JJ, Cole LJ. Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D. J Exp Med 1967, 126:109-125. 10.1084/jem.126.1.109, 2138307, 6027642.
38. Roldan E, Brieva JA. Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol 1991, 21:2671-2677. 10.1002/eji.1830211105, 1936115.
39. Pelletier N, Casamayor-Palleja M, De Luca K, Mondiere P, Saltel F, Jurdic P, Bella C, Genestier L, Defrance T. The endoplasmic reticulum is a key component of the plasma cell death pathway. J Immunol 2006, 176:1340-1347.
40. Hofer T, Muehlinghaus G, Moser K, Yoshida T, Mei HE, Hebel K, Hauser A, Hoyer B, E OL, Dorner T, Manz RA, Hiepe F, Radbruch A. Adaptation of humoral memory. Immunol Rev 2006, 211:295-302. 10.1111/j.0105-2896.2006.00380.x, 16824136.
41. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, Hardie DL, Bird R, MacLennan IC. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 2009, 182:2113-2123. 10.4049/jimmunol.0802771, 19201864.
42. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002, 169:4213-4221.
43. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004, 20:707-718. 10.1016/j.immuni.2004.05.001, 15189736.
44. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, Lee JJ, Lohning M, Berek C. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011, 12:151-159.
45. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, McKee T, Huard B. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood 2011, 118:1838-1844. 10.1182/blood-2011-01-332940, 21642598.
46. Winter O, Moser K, Mohr E, Zotos D, Kaminski H, Szyska M, Roth K, Wong DM, Dame C, Tarlinton DM, Schulze H, MacLennan IC, Manz RA. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010, 116:1867-1875. 10.1182/blood-2009-12-259457, 20538807.
47. Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med 2011, 208:1435-1446. 10.1084/jem.20110040, 3135367, 21690252.
48. Rodriguez Gomez M, Talke Y, Goebel N, Hermann F, Reich B, Mack M. Basophils support the survival of plasma cells in mice. J Immunol 2010, 185:7180-7185. 10.4049/jimmunol.1002319, 21068399.
49. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111:2755-2764. 10.1182/blood-2007-09-110858, 18180376.
50. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006, 18:265-270. 10.1016/j.coi.2006.03.004, 16616478.
51. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, Walker EU, Manz RA, Tarlinton DM, Smith KG. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007, 8:419-429. 10.1038/ni1440, 17322888.
52. Hutloff A, Buchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, Kroczek RA. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220. 10.1002/art.20519, 15476242.
53. Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G, Berek C, Hiepe F, Krenn V, Radbruch A, Manz RA. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001, 31:2726-2732. 10.1002/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H, 11536171.
54. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch AH, Burmester GR, Hiepe F, Dorner T. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with SLE. Ann Rheum Dis 2010, 69:305-308. 10.1136/ard.2008.096495, 19196727.
55. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003, 62:534-539. 10.1136/ard.62.6.534, 1754566, 12759290.
56. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755. 10.1038/nm1763, 18542049.
57. Frohlich K, Holle JU, Aries PM, Gross WL, Moosig F. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011, 70:1344-1345. 10.1136/ard.2010.133256, 21173019.
58. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol 2005, 560:125-139. 10.1007/0-387-24180-9_16, 15934172.
59. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992, 12:2662-2672. 364460, 1375324.
60. Cabanillas F, Burke JS, Smith TL, Moon TE, Butler JJ, Rodriguez V. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med 1978, 138:413-418. 10.1001/archinte.1978.03630270051019, 629636.
61. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. Embo J 1998, 17:2319-2333. 10.1093/emboj/17.8.2319, 1170575, 9545244.
62. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999, 401:556-562. 10.1038/44076, 10524622.
63. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007, 8:463-470. 10.1038/ni1454, 17440452.
64. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995, 18:385-397. 10.3109/10428199509059636, 8528044.
65. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983, 131:244-250.
66. Anderson KC, Griffin JD, Bates MP, Slaughenhoupt BL, Schlossman SF, Nadler LM. Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Methods 1983, 61:283-292. 10.1016/0022-1759(83)90222-3, 6348160.
67. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987, 70:1316-1324.
68. Maecker HT, Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997, 185:1505-1510. 10.1084/jem.185.8.1505, 2196279, 9126932.
69. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, Ferster A, Kuo CC, Levy S, van Dongen JJ, van der Burg M. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010, 120:1265-1274. 10.1172/JCI39748, 2846042, 20237408.
70. Dobbs AK, Bosompem A, Coustan-Smith E, Tyerman G, Saulsbury FT, Conley ME. Agammaglobulinemia associated with BCR B cells and enhanced expression of CD19. Blood 2011, 118:1828-1837. 10.1182/blood-2011-01-330472, 3158715, 21693761.
71. Artac H, Reisli I, Kara R, Pico-Knijnenburg I, Adin-Cinar S, Pekcan S, Jol-van der Zijde CM, van Tol MJ, Bakker-Jonges LE, van Dongen JJ, van der Burg M, van Zelm MC. B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele. Genes Immun 2010, 11:523-530. 10.1038/gene.2010.22, 20445561.
72. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, Franco JL. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901-1912. 10.1056/NEJMoa051568, 16672701.
73. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
74. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000, 18:393-422. 10.1146/annurev.immunol.18.1.393, 10837064.
75. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995, 3:39-50. 10.1016/1074-7613(95)90157-4, 7542548.
76. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995, 376:352-355. 10.1038/376352a0, 7543183.
77. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997, 186:1923-1931. 10.1084/jem.186.11.1923, 2199156, 9382890.
78. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999, 94:3551-3558.
79. Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, Mohan C, Nachman PH, Clarke SH. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J Clin Immunol 2007, 27:53-68. 10.1007/s10875-006-9051-1, 17195045.
80. Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL, Martin T. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun 2010, 34:426-434. 10.1016/j.jaut.2009.11.002, 19963348.
81. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927. 10.1002/art.20274, 15188368.
82. Odendahl M, Keitzer R, Wahn U, Hiepe F, Radbruch A, Dorner T, Bunikowski R. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:851-858. 10.1136/ard.62.9.851, 1754662, 12922958.
83. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, Berek C, Hiepe F, Manz R, Radbruch A, Dorner T. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105:1614-1621. 10.1182/blood-2004-07-2507, 15507523.
84. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lip sky PE, Radbruch A, Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
85. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51:364-369. 10.1136/jcp.51.5.364, 500695, 9708202.
86. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010, 335:213-222. 10.1124/jpet.110.168062, 20605905.
87. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards J O, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008, 68:8049-8057. 10.1158/0008-5472.CAN-08-2268, 18829563.
88. Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, Clarke SH. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol 2008, 126:189-201. 10.1016/j.clim.2007.10.004, 2812414, 18077220.
89. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH, Warnatz K. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004, 113:161-171. 10.1016/j.clim.2004.05.010, 15451473.
90. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, Zheng B, Milner EC, Bernstein SH, Sanz I, Zand MS. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 2007, 109:1611-1619. 10.1182/blood-2006-03-008441, 1794051, 17032927.
91. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009, 9:235-245. 10.1038/nri2524, 2779527, 19319142.
92. Warnatz K, Wehr C, Drager R, Schmidt S, Eibel H, Schlesier M, Peter HH. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology 2002, 206:502-513. 10.1078/0171-2985-00198, 12607725.
93. Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr 1974, 52:511-515. 10.1007/BF01468720, 4853392.
94. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?. Immunol Today 1990, 11:406-410.
95. Ellyard JI, Avery DT, Phan TG, Hare NJ, Hodgkin PD, Tangye SG. Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood 2004, 103:3805-3812. 10.1182/blood-2003-09-3109, 14701691.
96. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002, 99:2154-2161. 10.1182/blood.V99.6.2154, 11877292.
97. Withers DR, Fiorini C, Fischer RT, Ettinger R, Lipsky PE, Grammer A C. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 2007, 109:4856-4864. 10.1182/blood-2006-08-043414, 1885535, 17299094.
98. Arce S, Luger E, Muehlinghaus G, Cassese G, Hauser A, Horst A, Lehnert K, Odendahl M, Honemann D, Heller KD, Kleinschmidt H, Berek C, Dorner T, Krenn V, Hiepe F, Bargou R, Radbruch A, Manz RA. CD38low IgG-secreting cells are precursors of various CD38high-expressing plasma cell populations. J Leukoc Biol 2004, 75:1022-1028. 10.1189/jlb.0603279, 15020647.
99. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993, 81:2658-2663.
100. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, Nutt SL. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med 2004, 200:967-977. 10.1084/jem.20040973, 2211847, 15492122.
101. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006, 24:269-281. 10.1016/j.immuni.2006.01.012, 16546096.
102. Nera KP, Kohonen P, Narvi E, Peippo A, Mustonen L, Terho P, Koskela K, Buerstedde JM, Lassila O. Loss of Pax5 promotes plasma cell differentiation. Immunity 2006, 24:283-293. 10.1016/j.immuni.2006.02.003, 16546097.
103. Medina F, Segundo C, Campos-Caro A, Salcedo I, Garcia-Poley A, Brieva JA. Isolation, maturational level, and functional capacity of human colon lamina propria plasma cells. Gut 2003, 52:383-389. 10.1136/gut.52.3.383, 1773543, 12584220.
104. Di Niro R, Mesin L, Raki M, Zheng NY, Lund-Johansen F, Lundin KE, Charpilienne A, Poncet D, Wilson PC, Sollid LM. Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. J Immunol 2010, 185:5377-5383. 10.4049/jimmunol.1001587, 20935207.
105. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990, 76:1739-1747.
106. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342. 10.1002/art.10949, 12746906.
107. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
108. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann K G, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F. Takayasu-arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012, 71:75-79. 10.1136/ard.2011.153007, 21953334.
109. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dorner T. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171. 10.1002/art.10445, 12209521.
110. Martinez-Gamboa L, Mei H, Loddenkemper C, Ballmer B, Hansen A, Lipsky PE, Emmerich F, Radbruch A, Salama A, Dorner T. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 2009, 130:199-212. 10.1016/j.clim.2008.09.009, 18977183.
111. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999. 10.1002/art.23902, 18821683.
112. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011, 63:3038-3047. 10.1002/art.30466, 21618204.
113. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002, 206:519-527. 10.1078/0171-2985-00200, 12607727.
114. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477. 10.1002/art.22603, 17469105.
115. Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rumke P, Melief CJ. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother CII 1991, 32:364-372.
116. Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother CII 1995, 40:37-47.
117. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009, 113:4352-4361. 10.1182/blood-2008-09-179143, 19147785.
118. Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br J Cancer 1995, 72:1373-1379. 10.1038/bjc.1995.517, 2034088, 8519647.
119. Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999, 5:2392-2398.
120. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005, 102:15178-15183. 10.1073/pnas.0505539102, 1257712, 16217038.
121. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996, 157:4371-4378.
122. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997, 6:107-118. 10.1016/S1074-7613(00)80418-5, 9047233.
123. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977. 10.1126/science.1158545, 18703743.
124. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE. The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113:3735-3743. 10.1182/blood-2008-10-182048, 19109559.
125. Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC, Pan C, Preston B, Passmore D, Liu J, Kuhne MR, Witte A, Blanset D, King DJ. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother CII 2010, 59:257-265.
126. Liu XY, Pop LM, Tsai L, Pop IV, Vitetta ES. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines. Int J Cancer 2011, 129:497-506. 10.1002/ijc.25695, 20878959.
127. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102. 10.1182/blood-2010-04-281931, 2993617, 20668228.
128. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009, 32:689-702. 10.1097/CJI.0b013e3181ac6138, 2747302, 19561539.
129. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720. 10.1182/blood-2011-10-384388, 22160384.
130. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849, 3387277, 21830940.
131. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822-1826. 10.1172/JCI46110, 3083795, 21540550.
132. Ochtrop ML, Goldacker S, May AM, Rizzi M, Draeger R, Hauschke D, Stehfest C, Warnatz K, Goebel H, Technau-Ihling K, Werner M, Salzer U, Eibel H, Schlesier M, Peter HH. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood 2011, 118:309-318. 10.1182/blood-2010-11-321695, 21576700.
133. Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, Eibel H, Schlesier M, Peter HH. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007, 124:294-303. 10.1016/j.clim.2007.04.011, 17602874.
134. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257-2259.
135. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81. 10.1002/art.25033, 20039396.
136. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007, 66:1402-1403. 10.1136/ard.2007.071878, 1994303, 17881666.
137. Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74. 10.1002/art.25034, 20039397.
138. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010, 12:R111. 10.1186/ar3047, 2911904, 20529331.
139. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
140. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, doubleblind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627.
141. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840. 10.1182/blood-2008-10-186999, 2686134, 19264918.
142. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992, 256:105-107. 10.1126/science.1373518, 1373518.
143. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007, 56:2715-2718. 10.1002/art.22811, 17665440.
144. Mielke F, Schneider-Obermeyer J, Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008, 67:1056-1057.
145. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007, 13:1365-1368. 10.1002/ibd.20215, 17604367.
146. Benedetti L, Franciotta D, Vigo T, Grandis M, Fiorina E, Ghiglione E, Roccatagliata L, Mancardi GL, Uccelli A, Schenone A. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch Neurol 2007, 64:1531-1533. 10.1001/archneur.64.10.1531, 17923639.
147. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8:391-397. 10.1038/nri2315, 18437156.
148. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32:129-140. 10.1016/j.immuni.2009.11.009, 20079667.
149. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541. 10.1182/blood-2010-07-294249, 3031478, 20962324.
150. Lorenzi AR, Clarke AM, Wooldridge T, Waldmann H, Hale G, Symmons D, Hazleman BL, Isaacs JD. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum 2008, 58:370-375. 10.1002/art.23122, 18240243.
151. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair EW, Schnitzer TJ, Johnston JM. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol 1996, 35:231-240. 10.1093/rheumatology/35.3.231, 8620297.
152. Isaacs JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, Waldmann H, Hale G, Hazleman BL. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001, 44:1998-2008. 10.1002/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T, 11592360.